Dr. ZHANG is a core expert in hematologic oncology rehabilitation at the China Cancer Foundation and was recognized as one of China’s TOP 10 Best Doctors in 2020. Her research primarily focuses on tumor immunotherapy in hematological malignancies. She has authored multiple articles published in Blood, Leukemia and so on, with a total impact factor exceeding 100. She also served as the associate editor of China’s first “Clinical Management Pathway Guidelines for CAR-T Treatment of NHL Adverse Effects,” published in 2021.